KBY Biotech Indexv0.0.34
Search
← Pipeline|Kemanesiran

Kemanesiran

Phase 3
CAM-1414
By Camurus
Source: Trial-derived·Trials: 1
Modality
ERT
MOA
Anti-Tau
Target
KRASG12D
Pathway
Apoptosis
MDS
Development Pipeline
Preclinical
~Nov 2020
→ ~Feb 2022
Phase 1
~May 2022
→ ~Aug 2023
Phase 2
~Nov 2023
→ ~Feb 2025
Phase 3
May 2025
→ Nov 2028
Phase 3Current
NCT05862798
1,923 pts·MDS
2025-05→2028-11·Terminated
1,923 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-11-282.7y awayPh3 Readout· MDS
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Termina…
Catalysts
Ph3 Readout
2028-11-28 · 2.7y away
MDS
Terminated|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT05862798Phase 3MDSTerminated1923BodyWt
Competitors (10)
DrugCompanyPhaseTargetMOA
RHH-7558RochePhase 1SGLT2Anti-Tau
NVS-5439NovartisPreclinicalBETAnti-Tau
RilulemzoparlimabNovartisPhase 2/3KRASG12DPD-L1i
BMY-2495Bristol-Myers SquibbPhase 3KRASG12DALKi
SNY-2934SanofiPhase 3KRASG12DUSP1i
TalainavolisibNovo NordiskPreclinicalKRASG12DPRMT5i
NVO-9630Novo NordiskPhase 2CD3Anti-Tau
GIL-2037Gilead SciencesApprovedKRASG12DMDM2i
REG-2172RegeneronPhase 1/2PCSK9Anti-Tau
BGN-3305BeiGenePhase 2BCMAAnti-Tau